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1. Introduction 
Several melanoma antigens, recognized by autologous cytotoxic T lymphocytes, have been 
identified (Boon and van der Bruggen, 1996). The antigens can be divided into two separate 
groups, (a) antigens associated with pigment formation such as tyrosinase (Wölfel et al., 
1994), tyrosinase related protein (TRP)-1 (Wang et al., 1995), TRP-2 (Wang et al., 1996), 
MART-1/Melan-A (Coulie et al., 1994; Kawakami et al., 1994a) and gp100/Pmel 17 
(Kawakami et al., 1994b) present in normal as well as malignant cells of melanocytic lineage, 
and (b) tumour associated antigens of the MAGE-, BAGE- and GAGE-families that are 
found in many different malignant cells (Brasseur et al., 1995). These antigens are presented 
on the cell surface by HLA class I molecules and are important in the immune surveillance 
of tumour cells and several of these antigens have been utilized in vaccination studies 
(Parmiani et al., 2002). 
In addition to being investigated for their role in the immune response, mRNAs of these 
antigens, especially tyrosinase, have been used for detection of circulating melanoma cells in 
blood (Brownbridge et al., 2001; de Vries et al., 1999; Hoon et al., 1995; Johansson et al., 2000; 
Reynolds et al., 2003; Smith et al., 1991). In this context there are great variations in the 
results (for a review see (Keilholz et al., 1997)) and the usefulness of this technique is 
disputed (Hanekom et al., 1999; Mellado et al., 1999; Osella Abate et al., 2000). The variations 
may be due to several factors, e.g. differences in the methods used and in the selection of 
participating patients. Low concentrations of the transcripts in the tumours would be 
reflected in a low detection rate of melanoma cells in blood and high transcript 
concentrations would result in a higher probability of detecting cells present in blood.  
Several of these antigens have earlier been studied by immunohistochemical and 
conventional RT-PCR methods. A great heterogeneity in the frequency of expression of 
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tyrosinase, MART-1/Melan-A, and gp100/Pmel 17 protein in different melanocytic lesions 
and melanoma cell lines has been shown (Cormier et al., 1998; de Vries et al., 1997; Sarantou 
et al., 1997). Similarly, loss of mRNA expression of one or more of the antigens tyrosinase 
TRP-1, TRP-2, MART-1/Melan-A, and gp100/Pmel 17 was found in 26 % of primary and 
metastatic tumours (Sarantou, et al., 1997). In addition, Dalerba et al. (Dalerba et al., 1998) 
found a variable mRNA expression of tyrosinase, MART-1/Melan-A, MAGE-A1, MAGE-
A2, MAGE-A3, BAGE and GAGE between multiple in-transit and lymph-node metastases. 
However, the above mentioned studies did not provide quantitative information. Thus, 
better understanding of mRNA levels and the factors influencing the expression of these 
antigens is needed. 
We have therefore determined the mRNA concentrations of tyrosinase, TRP-1, TRP-2, 
MART-1/Melan-A, MAGE-A3, MAGE-A12, S-100 and GD2 synthase in sections of snap 
frozen melanoma metastases from treated and untreated patients. Furthermore, we have 
compared two different methods, use of section area and use of housekeeping genes for 
normalization of the expression data for differences in starting amounts of tissue. In 
addition, we have investigated the influence of tumour-infiltrating lymphocytes on the 
expression of these antigens. 
2. Material and methods 
2.1 Tumour material 
Melanoma metastases from 7 women and 21 men with regional and systemic disease were 
investigated. The median age of the patients was 50 years (range 26 to 82 years) and 
treatment for metastatic disease was given to 15 of the patients before removal of the 
metastases. Recurrences were cytologically verified by fine needle aspiration biopsy before 
start of treatment. One metastasis from each patient was studied. In patients with systemic 
disease easily resectable metastases were chosen. In patients with regional disease, non-
necrotic biopsies were randomly chosen by the pathologist. Only sections of good technical 
quality were included in the study. Thus, sections that were either crackled or damaged, or 
contained large necrotic areas, or mainly contained lymph node remnants were excluded. 
The study was approved by the ethical committee at the University Hospital in Linköping, 
Sweden. 
The treatment schedule was cisplatinum 30 mg/m2 i.v., dacarbazine (DTIC) 250 mg/m2 i.v. 
day 1-3 and interferon-α2b 10 million IU s.c. three times weekly. The duration of each cycle 
was 28 days. 
The tumours were snap frozen after resection and stored at -70°C until further processed. 
Three parallel sections (7 µm) were cut from each metastasis and two of them were 
immediately transferred to 500 µl of lysis buffer (100 mM Tris-HCl pH 7.6, 500 mM LiCl, 10 
mM EDTA, 5 mM DTT, 1% SDS) and homogenized using a Mikro-Dismembrator S (B. 
Braun Biotech International GmbH, Melsungen Germany). The third section was used for 
conventional light microscopy studies. 
2.2 Analysis of mRNA expression 
The lysate was added to 100 µl GenoPrep mRNA Beads (GenoVision , Oslo, Norway) and 
the mixture was incubated on a rotating mixer for 10 min. The magnetic beads were 
immobilized using a Dynal MPC-S device (Dynal Biotech, Oslo, Norway) and washed twice 
in 1 ml 10 mM Tris-HCl, pH 7.6, containing 150 mM LiCl, 1 mM EDTA, and 0.1 % SDS and 
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then twice in 1 ml 10 mM Tris-HCl, pH 7.6, containing 150 mM LiCl, and 1 mM EDTA. 
mRNA was released from the magnetic beads in 20 µl RNase-free water by incubation at 
70°C for 2 min. First strand cDNA was synthesized using random hexamers and Moloney 
Murine Leukemia Virus reverse transcriptase as described earlier (Johansson, et al., 2000). 
 
Oligonucleotide Sequence 
Conc. 
(nM) 
Tyrosinase FP ATGGATAAAGCTGCCAATTTCA 100 
Tyrosinase RP GGCATCCGCTATCCCAGTA 100 
Tyrosinase Probe CTTTAGAAATACACTGGAAGGATTTGCTAGTCCAC 50 
TRP-1 FP TCATGAGGGACCAGCTTTTC 100 
TRP-1 RP TCTTGCAACATTTCCTGCAT 100 
TRP-1 Probe CACATGGCACAGGTACCACCACCT 50 
TRP-2 FP GGAAAGAGATCTCCAGCGAC 100 
TRP-2 RP ATCACACTCGTTCCTCCCA 100 
TRP-2 Probe TGCTTTGCCCTACTGGAACTTTGCC 50 
MART-1/Melan-A FP GCCACTCTTACACCACGGC 100 
MART-1/Melan-A RP TCCCAGGATCACTGTCAGGA 100 
MART-1/Melan-A Probe GCCGATCCCAGCGGCCTCTT 100 
S-100 FP CCATTTCTTAGAGGAAATCAAAGAG 100 
S-100 RP ATTCGCCGTCTCCATCAT 100 
S-100 Probe TGTCCAGTGTTTCCATGACTTTGTCCA 100 
GD2 synthase FP CCAGGGAGCCCAGTACAAC 100 
GD2 synthase RP GCCGTGAAGACGAAGTCG 100 
GD2 synthase Probe AACCAGCCCTTGCCGAAGGGC 200 
MAGE-A3 FP TGAGGAGGCAAGGTTCTGA 100 
MAGE-A3 RP ATGGAGACCCACTGGCAG 100 
MAGE-A3 Probe TCTGGTCCTCCAGGTCAGCCTGT 100 
MAGE-A12 FP GTGAGGAGGCAAGGTTCTG 100 
MAGE-A12 RP GGCATGATGACTCTGGTCAG 100 
MAGE-A12 Probe TCCTGCCCACACTCCTACCTGCT 50 
Table 1. Sequences and concentrations of primers and probes used in real-time PCR for 
melanoma transcripts 
  
Transcript Forward primer Reverse primer 
Tyrosinase TTGGCAGATTGTCTGTAGCC AGGCATTGTGCATGCTGCTT 
TRP-1 AAAGCTTTGGTGAAGTGGATTT AGACCACTCGCCATTGAGA 
TRP-2 CTACAGGGCCATAGATTTCTC GTTGTAGTCATCCAAGCTATCAC 
MART-1/Melan-A GACTCTCATTAAGGAAGGTGTCC TTGTTAAGGCACATTGAGTGC 
S-100 GGGAGACAAGCACAAGCTGAAG TTCAAAGAACTCGTGGCAGGCAGT 
GD2 synthase CCAGGGAGCCCAGTACAAC GCCGTGAAGACGAAGTCG 
MAGE-A3 TGAGGAGGCAAGGTTCTGA ATGGAGACCCACTGGCAG 
MAGE-A12 GAGGTCAGAGAACAGCGAGATT CCGCAGGGTGACTTCC 
Table 2. Primers used for synthesis of calibrators 
The cDNA was diluted 1:10 before further analysis. From these samples 2.5 µl was analyzed 
in triplicates by PCR in a total volume of 25 µl (Johansson, et al., 2000).  
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The mRNAs of tyrosinase, TRP-1, TRP-2, MART-1/Melan-A, MAGE-A3, MAGE-A12, S-100, 
and GD2 synthase were analyzed by real-time PCR using the ABI Prism 7700 Sequence 
Detector System (Applied Biosystems, Foster City, California, USA). All transcripts were 
analyzed using the same protocol, 1 x TaqMan PCR Buffer (Applied Biosystems), 5 mM 
MgCl2 (Applied Biosystems), 200 µM dNTPs (Amersham Biosciences, Uppsala, Sweden), 
and 0.025 U/µl AmpliTaq Gold (Applied Biosystems) (Johansson, et al., 2000) with the 
respective primer and probe concentration (Table 1). The oligonucleotides were bought from 
Scandinavian Gene Synthesis (Köping, Sweden). Their sequences are shown in Table 1.  
For each transcript, a specific cDNA calibrator was synthesized using primers located 
outside the analytical primers (Table 2). The PCR product was quantified by limiting 
dilution and Poisson distribution as described earlier (Johansson et al., 2002). The calibrators 
were analyzed in ten-fold dilutions from 100 000 to 10 transcripts/µl in each PCR run. 
Three different housekeeping genes, hypoxanthine ribosyl transferase (HPRT),  
ǃ-glucuronidase (GUS) and ǃ2-microglobulin (B2M), were amplified using Pre-Developed 
Assay Reagents from Applied Biosystems. Serial dilutions of cDNA from IMR-32 
neuroblastoma cells were used as calibrators. To be able to combine the three housekeeping 
genes to one normalization factor the expression data of each housekeeping gene need to be 
at the same level as the others. As the three housekeeping genes differed in their level of 
expression (Kågedal et al., 2007), a relative expression of each housekeeping gene was 
defined as the percentage expression of the individual metastasis compared with the mean 
of all metastases for each housekeeping gene. The mean of the relative expression of the 
three housekeeping genes was used for normalization. The calculation of the normalization 
factor (NF) is described by the following equation: 
 2
2
100 100 100 3iHPRT iGUS iB Mi
HPRT GUS B M
x x x
NF
x x x
⎛ ⎞= ⋅ + ⋅ + ⋅⎜ ⎟⎝ ⎠  (1) 
where ix  is the expression of the respective housekeeping gene in the individual sample 
and x  is the respective mean expression. 
 
% tumor in section
40 50 60 70 80 90
E
x
p
re
s
s
io
n
 o
f 
ty
ro
s
in
a
s
e
 (
tr
a
n
s
c
ri
p
t/
m
m
2
)
0
50000
100000
150000
% tumor in section
40 50 60 70 80 90
E
x
p
re
s
s
io
n
 o
f 
M
A
G
E
-A
3
 (
tr
a
n
s
c
ri
p
t/
m
m
2
)
0
5000
10000
15000
20000
25000
30000
A B
 
Fig. 1. Expression of tyrosinase (A) and TRP-1 (B) plotted against the tumour content of 
tissue section of melanoma metastases. The amounts of transcript are given normalized to 
the area of the respective section 
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2.3 Staining of sections and evaluation of tumour cells and lymphocytes 
The sections used for microscopy were stained with hematoxylin and eosin and mounted in 
Mountex (Histolab products AB, Göteborg, Sweden). The amounts of tumour-infiltrating 
lymphocytes were semi-quantitatively scored as <5%, 5-10%, 10-15%, 15-20% and >20%. 
Metastases scored as <5% were considered to contain low amounts of such cells. The 
amounts of tumour in the sections were also semi-quantitatively scored to the nearest decile. 
The scores were made by two independent observers (AH, BG). The sections were also 
photographed and the area of the sections was measured using the shareware NIH Image 
1.63 (http://rsb.info.nih.gov/nih-image/download.html). 
2.4 Statistics 
Correlations were evaluated using Pearson’s correlation coefficient. The Mann-Whitney  
U-test was used to compare expression of melanoma associated antigens in sections with 
different amounts of tumour-infiltrating cells and in metastases from untreated and treated 
patients. 
3. Results 
The present study is based on analysis of melanoma associated transcripts in 7 µm thick 
tissue sections from frozen melanoma metastases. Histological analysis of parallel section 
was performed and biopsies with necrotic areas and lymph node remnants of more than 30 
per cent of the section area were not included. The amount of tumour cells was scored and 
found to vary between 40 per cent and more than 90 per cent of the section area. 
 
 aTranscripts/mm2 bTranscripts/HKG 
 Mean SD Median Range Mean SD Median Range 
Tyrosinase 61 000 56 000 48 000 7-180 000 32 000 24 000 25 000 9-94 000 
TRP-1 28 000 57 000 1 600 0-210 000 11 000 17 000 1 300 0-59 000 
TRP-2 65 000 100 000 16 000 150-410 000 40 000 65 000 12 000 130-260 000 
MART-1/Melan-A 120 000 120 000 77 000 520-450 000 63 000 54 000 45 000 360-200 000 
S-100 91 000 123 000 45 000 960-530 000 46 000 63 000 27 000 6 800-310 000 
GD2 synthase 560 670 410 13-2 900 280 410 150 22-2 200 
MAGE-A3 10 000 10 000 8 500 36-33 000 4 800 4 400 4 300 36-21 000 
MAGE-A12 4 300 5 000 2 100 0-18 000 1 900 2 200 1 400 0-9 800 
aThe results were normalized to the area of the sections.  
bThe results were normalized to the mean expression of the housekeeping genes (HKG) HPRT, GUS 
and B2M. 
Table 3. Expression of melanoma-associated antigens in metastatic lesions 
No significant correlations were found between any transcript concentration and the per 
cent tumour in the sections. This is illustrated in Fig. 1 for tyrosinase and MAGE-A3.  
To account for differences in the amounts of starting material, the results of the mRNA 
analysis were normalized to the tissue section areas measured in parallel sections. The areas 
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of the tumour sections varied between 7 and 124 mm2. For comparison the mean of three 
housekeeping genes was also used in order to normalize the transcript expression data.  
For each transcript, there was a large variation between the metastases. Also the mean levels 
of the different transcripts varied greatly. The pigment-related transcripts (tyrosinase, TRP-1, 
TRP-2, and MART-1/Melan-A) and that of S-100 had the highest concentrations and widest 
range (Table 3). For TRP-1 and to some extent for TRP-2, the median was low compared to 
the mean, which was due to a very low expression in a high proportion of the metastases 
(Fig. 2). MAGE-A3 and MAGE-A12 were expressed at a somewhat narrower range, whereas 
GD2 synthase was expressed at even lower levels.  
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Fig. 2. Expression of (A) tyrosinase, (B) TPR-1, (C) TRP-2, and (D) MART-1/Melan-A 
mRNAs in frozen sections from malignant melanoma metastases (n=28). The results are 
given normalized to the area of parallel tissue sections 
When housekeeping genes were used for normalization, there was a tendency to less 
variation of the data, c.f. range of the data (Table 3). Fig. 3 shows the comparison of the two 
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ways of normalization for tyrosinase and MAGE-A3 data of the metastases containing 90 % 
tumour. It can be seen that some of the highest expressing metastases were equalized when 
housekeeping genes were used for normalization. Thus, there were transpositions in the 
orders regarding the amounts of transcripts depending on normalization. There were 
significant correlations (p<0.05) for all transcripts when normalized by the two methods, but 
there were great variations around the regression line (data not shown). 
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Fig. 3. Comparison of the two methods used for normalization of mRNA data, exemplified 
by (A) tyrosinase and (B) MAGE-A3 expression. The results normalized to area of the 
section (gray bars) and to the expression of the three housekeeping genes (black bars) are 
shown for the metastases containing 90% tumour. The metastases were sorted by the results 
normalized to area for each transcript 
The correlations between the expressions of the different transcripts were examined. Among 
the pigment-related transcripts a strong correlation was found between tyrosinase and 
MART-1/Melan-A (p<0.001, R=0.67, Fig. 4A). Weaker correlations (p<0.01, R=0.57 and 
R=0.49 respectively) were found between the two pairs tyrosinase–TRP-1 and  
TPR-2–MART-1/Melan-A (data not shown). However, the appearance of these weaker 
correlations was mainly due to high expressions of these antigens in a few sections. The 
MAGE-antigens MAGE-A3 and MAGE-A12 also correlated strongly with each other 
(p<0.001, R=0.76, Fig. 4B). Interestingly when biopsies from treated and untreated patients 
were analyzed separately, MAGE-A3 was significantly correlated with tyrosinase and 
MART-1/Melan-A in the sections from the treated patients (Fig. 5, p<0.01, R=0.66 and 0.71 
respectively). 
When the total material was analyzed, the occurrence of tumour infiltrating lymphocytes 
did not seem to influence the expression of the genes (12 tumours contained low and 16 
contained high amounts of tumour infiltrating lymphocytes). However, if only metastases 
from untreated patients were analyzed, there was a significantly lower (p<0.05) expression 
of MART-1/Melan-A and S-100 in the metastases containing high amount of tumour-
infiltrating lymphocytes (n=5 and n=8 for low and high respectively, data not shown). These 
differences were not present in the treated patients. 
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Fig. 4. Correlations between (A) tyrosinase and MART-1/Melan-A expression, and between 
(B) MAGE-A3 and MAGE-A12 expression in melanoma metastases. The expression data 
were normalized to the section area 
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Fig. 5. Correlations of MAGE-A3 with (A) tyrosinase and (B) MART-1/Melan-A in treated 
patients (n=15). The expression data were normalized to the section area to account for 
differences in starting amount 
The influence of treatment on the mRNA expression was also investigated (Table 4). A 
significant effect was obtained in TRP-2 expression, where the treated tumours (n=15) 
showed an increased expression (p<0.05) as compared with the untreated tumours (n=13). 
The GD2 synthase expression on the other hand was decreased in the treated group (p<0.05). 
With all other transcripts, no significant differences were found. 
As the tumour-infiltrating lymphocytes could be of importance for the expression of the 
antigens, we substratified the sections according to low or high infiltration of tumour-
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infiltrating lymphocytes (<5% was used as cut-off) before comparing data from untreated 
and treated patients (Table 4). No difference in TRP-2 expression was found in any of the 
groups. With GD2 synthase, the decrease in the treated patients remained in the metastases 
containing high amounts of tumour-infiltrating lymphocytes. For the other genes the only 
difference found was in tyrosinase expression, which was decreased in metastases from 
treated patients, but only in metastases containing low amounts of tumour-infiltrating 
lymphocytes. In table 4 the results are also given normalized by housekeeping genes. In 
addition to the differences found when normalized by area, increased expression of 
tyrosinase, MART-1/Melan-A, and S-100 in treated patients were found in the metastases 
containing high amounts of tumour-infiltrating lymphocytes. 
 
 All metastasesa Tumour-infiltrating  lymphocytes lowb 
Tumour-infiltrating  
lymphocytes highc 
 Tr/mm2 Tr/HKG Tr/mm2 Tr/HKG Tr/mm2 Tr/HKG 
Tyrosinase NSd NS ↓ p=0.010 ↓ p=0.030 NS ↑ p=0.050 
TRP-1 NS NS NS NS NS NS 
TRP-2 ↑ p=0.019 ↑ p=0.003 NS ↑ p=0.048 NS NS 
MART-1/Melan-A NS NS NS NS NS ↑ p=0.021 
S-100 NS NS NS NS NS ↑ p=0.003 
GD2 synthase ↓ p=0.010 ↓ p=0.065 NS NS ↓ p=0.007 ↓ p=0.028 
MAGE-A3 NS NS NS NS NS NS 
MAGE-A12 NS NS NS NS NS NS 
aThe material comprised of 13 metastases from untreated patients and 15 metastases from treated 
patients. The results were normalized to the area of each section or to the mean expression of three 
housekeeping genes (HKG) as indicated. 
bMetastases containing <5% tumour-infiltrating lymphocytes, 5 metastases from untreated patients and 
7 metastases from treated patients. 
cMetastases containing ≥5% tumour-infiltrating lymphocytes, 8 metastases from untreated patients and 
8 metastases from treated patients. 
dNS = not significant. Significant increases and decreases in the treated patients compared with 
untreated patients are indicated by arrows. 
Table 4. Changes in the expression of melanoma associated transcripts in relation to treatment 
4. Discussion 
In gene expression studies the expression of specific transcripts is generally normalized to 
the expression of a housekeeping gene (Vandesompele et al., 2002). The rationale for 
simultaneous analysis of housekeeping genes is to compensate for different amounts of 
tissue taken to analysis, and for variations in the analytical process, e.g. degradation of 
mRNA, incomplete extraction etc. Usually housekeeping genes are chosen among genes of 
fundamental importance for cell metabolism and thus are supposed to be equally expressed 
in all cell types. However, there is no guarantee that they are adequate for normalization of 
transcripts in tumour studies as the metabolic and proliferative rates of tumours usually 
vary considerably with no relation to the expression of specific transcripts. Furthermore, 
tumour biopsies are usually heterogeneous partly due to the presence of cell types other 
than tumour cells, e.g. connective tissue and inflammatory cells. Housekeeping gene 
transcripts derived from such cells will of course limit the value of normalization of the 
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selected tumour cell transcripts, i.e. as a measurement of the amount of tumour cells taken 
to analysis. In addition, housekeeping genes might vary between different cell types and 
also between tumours (Lee et al., 2002; Vandesompele, et al., 2002), not necessarily in 
relation with the occurrence of tumour specific transcripts. Therefore, in the present study 
on the expression of melanoma associated transcripts, we have reported the transcript data 
normalized by the area of parallel tissue sections with defined thickness (7 µm).  
Based on histological examination, necrotic tumours and tumours with lymph node remnants 
of more than 30 per cent of the tissue section area were excluded from this material. The 
percentage of the tissues section areas comprised by tumour was also determined in this 
analysis and no correlation was found between expression of transcripts and the amount of 
tumour cells. This shows that the dominating source of variation of expression of tumour 
associated transcripts is due to individual variation between different tumour cell populations. 
In the present material of melanoma metastases we found that the housekeeping genes 
HPRT, GUS and B2M varied greatly between melanoma metastases, and in several cases 
with a large discrepancy between the genes when normalized to the area of the tissue sections 
(unpublished results). There can be several reasons for this variation besides variation in the 
composition of the biopsies analyzed. Housekeeping genes might be modulated by 
cytokines produced by inflammatory cells or by agents used in the treatment of the tumour.  
However, as housekeeping genes are usually used in these type of studies, we have also 
analyzed the transcript data normalized to the mean of the three housekeeping genes. 
Interestingly, a significant correlation between the two methods was found for all transcripts 
analyzed and the outcome of the statistical analysis when normalized to housekeeping 
genes was not as different from that obtained when using the section area as might be 
expected. A significant correlation between tyrosinase–MART-1/Melan-A and MAGE-A3–
MAGE-A12 was also found when the transcript expression data were normalized to the 
housekeeping genes. The effect of tumour infiltrating lymphocytes on MART-1/Melan-A 
expression found in metastases from untreated patient remained. This was not the case with 
S-100 expression. Similarly, the differences found in the comparison of metastases from 
untreated and treated metastases when normalized to the section area were also found 
when data were normalized to the housekeeping genes. However, when using housekeeping 
genes, treatment related increases of tyrosinase, MART-1/Melan-A and S100 expression 
were found in metastases containing tumour-infiltrating lymphocytes. These differences 
were also seen as weak tendencies, when the section area was used for normalization. 
As could be expected a wide variation in the expression of melanoma associated antigens 
between tumours was found irrespective of the method used for normalization. Similar 
results have also been reported by others (Ohnmacht et al., 2001; Riker et al., 2000). The 
difference in mRNA levels between the markers and tumours could be of importance for the 
detection of circulating melanoma cells in patients. A higher expression of transcript in each 
melanoma cell would facilitate the detection of transcripts in blood originating from a few 
circulating tumour cells. We found higher concentrations of the pigment-related transcripts 
than of the MAGE transcripts. These results could explain why patients are positive for 
tyrosinase more frequently than for MAGE-A3 in most studies analyzing several different 
melanoma markers (Berking et al., 1999; Hoon et al., 2000; Hoon, et al., 1995). One exception 
was reported by Reynolds et al. (Reynolds, et al., 2003), who detected MAGE-A3 mRNA in a 
slightly higher proportion of the patients than tyrosinase mRNA.  
Several mechanisms are likely to be involved in regulation of the expression of melanoma 
associated transcripts. We found a strong correlation between tyrosinase and  
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MART-1/Melan-A. This could perhaps be explained by the findings that both tyrosinase 
(Bentley et al., 1994; Yasumoto et al., 1994) and MART-1/Melan-A (Du et al., 2003) 
transcription is regulated by the microphtalmia transcription factor (MITF). MITF is also 
believed to be involved in the regulation of TRP-1 and TRP-2 (Yasumoto et al., 1997), 
however these two genes have also been reported to be regulated independently of 
tyrosinase (Fang et al., 2001; Fang and Setaluri, 1999). Thus, other mechanisms may be 
involved in the regulation of TRP-1 and TRP-2 expression. This may be the reason why the 
expression of the pigment-related transcripts was not strongly correlated with each other in 
the metastases studied here. Also the expression of the two MAGE transcripts, MAGE-A3 
and MAGE-A12, were strongly correlated with each other in the present study. Eradication 
of immunogenic tumour cell clones either spontaneously or induced by immunotherapy 
will change the occurrence of tumour associated antigens. The mRNA concentrations of 
these antigens are likely to be of importance for the presentation of antigens to the immune 
system, provided that there is a quantitative relation between mRNA and protein 
expression. A correlation between mRNA expression and recognition by cytotoxic T 
lymphocytes has been shown for gp100/Pmel17 (Riker, et al., 2000). Interestingly, there 
seemed to be a relation between the stage of the patient and the occurrence of tyrosinase and 
MAGE-A3. The detection rate of tyrosinase mRNA was higher in advanced melanoma 
whereas the detection rate of MAGE-A3 mRNA was higher in the earlier stages (Reynolds, 
et al., 2003). Furthermore, down regulation of tyrosinase and TRP-2 has been shown to 
correlate with a shorter survival (Takeuchi et al., 2003). 
Tumour cells have developed several mechanisms for immune escape. One way is a 
reduced presentation of antigens in HLA class I (Ohnmacht and Marincola, 2000). This can 
be accomplished either by down regulation of HLA or a decreased expression of the 
presented antigens. Immunohistochemical studies showed that vaccination with gp100 
peptide decreased the expression of gp100 in metastatic lesions (Riker et al., 1999). When 
vaccination with gp100 was combined with IL-2 treatment, a decrease was also observed in 
MART-1/Melan-A expression. In contrast to these findings, it was reported that MART-
1/Melan-A was expressed in a stable manner, as assessed by immunohistochemistry, in 
serial fine needle aspirates from melanoma patients undergoing peptide vaccination (Fetsch 
et al., 2001). However, studies on gene expression from repeated fine needle aspirates 
showed that gp100, MART-1/Melan-A and TRP-2 decreased after vaccination treatment, but 
only in the patients responding to treatment (Ohnmacht, et al., 2001). This might be due to 
differences in the sensitivity of the two methods and might still be compatible with 
eradication of the antigen positive clones. In the present study, only tyrosinase and GD2 
synthase expressions were decreased in treated melanomas compared to untreated. 
However, for tyrosinase this effect was found only in metastases that did not recruit 
lymphocytes. 
Apart from down regulation or selection due to immune mediated anti-tumour reactivity, 
the expression of melanoma antigens could be modulated by several other factors. The 
presence of tumour-infiltrating lymphocytes could affect the expression. Activated 
lymphocytes secrete various types of cytokines, which are involved in regulatory processes. 
It was shown that interferon-Ǆ up-regulated tyrosinase and MAGE-A3 in 4/10 and 4/18 cell 
lines (Hofbauer et al., 2001). This might explain why a treatment related down regulation of 
tyrosinase was found only in tumours with low numbers of tumour infiltrating lymphocytes 
since interferon-Ǆ produced by a high number of tumour-infiltrating lymphocytes might 
have up regulated tyrosinase (Hofbauer et al., 2001). 
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The drugs used for treatment could either modulate the mRNA expression or perhaps select 
clones with an altered expression. The patients in this study were treated with cisplatinum, 
DTIC, and interferon-α. Interferons have been shown to give mixed responses in the 
regulation of melanoma associated antigens in melanoma cultures. Interferon-α up 
regulated the expression of MAGE-A3 more than 50% in 5 of 18 melanoma cell cultures 
(Hofbauer et al., 2001). In the remaining cell lines the expression was either not affected or 
slightly decreased. In our study, however, there was no effect of treatment on the MAGE 
transcripts, which might be due to a possible up-regulation being counteracted by 
eradication of MAGE-A3 positive clones. This multi-factorial regulation of antigen 
expression can also explain why a correlation between MAGE-A3 expression and tyrosinase 
and MART-1/MelanA expression in the present study was found only in treated patients. 
It has also been speculated that some of the studied antigens can contribute to drug 
resistance. Hence, a selection of highly expressing clones would be expected. Elevated 
expression of several members of the MAGE and GAGE gene families have been found in 
paclitaxel resistant cell lines (Duan et al., 2003). Similarly, Pak et al. (Pak et al., 2000) have 
shown that melanoma cell lines resistant to cisplatinum had elevated levels of TPR-2. The 
resistance was independent of the expression of the other two transcripts of the tyrosinase 
family and no correlation was found between the melanin content of the cell lines and 
resistance. Thus, it was concluded that the protection against cisplatinum cytotoxicity is 
mediated through TRP-2 rather than through melanin. This observation can explain the 
treatment-related up-regulation of TRP-2 as the activity of cisplatinum is of importance for 
the therapeutic effect of the combination treatment given in the present study. TRP-2 
positive clones are thus likely to be protected from therapeutic eradication.  
Quantitative analysis of melanoma associated transcripts in tumour material is very 
complex partly because of problems in selection and use of housekeeping genes as 
discussed above and partly because of the complex regulation of the expression of these 
transcripts by cytokines produced by tumour infiltrating inflammatory cells and by the 
modulatory effects of therapeutic drugs. This study demonstrates that after all it is possible 
by careful analysis of the data to obtain biologically relevant results. 
5. Conclusion 
Several antigens expressed in malignant melanoma are involved in the immunological 
surveillance of the tumour. The mRNAs of these antigens, especially tyrosinase, have also 
been used in the detection of minimal residual disease in the blood of melanoma patients. 
We have therefore analyzed the expression of tyrosinase, TRP-1, TRP-2, MART-1/Melan-A, 
MAGE-A3, MAGE-A12, S-100 and GD2 synthase by real-time PCR in snap frozen sections 
from 28 regional and systemic metastases. Treatment with cisplatinum, dacarbazine and 
interferon-α2b was given to 15 patients before surgery. The transcript concentrations varied 
widely between individual metastases. However, in general the pigment-related transcripts 
and that of S-100 were found at higher levels than those of MAGE-A3, MAGE-A12 and GD2 
synthase. Significant correlations (p<0.001) were found between tyrosinase and MART-
1/Melan-A and between MAGE-A3 and MAGE-A12. TRP-2 and GD2 synthase were both 
influenced by the treatment, TRP-2 expression was increased in the metastases from treated 
patients, whereas GD2 synthase expression was decreased. Furthermore, a decrease in 
tyrosinase expression was found in metastases without tumour-infiltrating lymphocytes. In 
this work normalization by the section area contra normalization by housekeeping genes 
was also evaluated and similar results were obtained with the two methods.  
www.intechopen.com
Expression of Tumour Associated Transcripts in  
Malignant Melanoma Metastases - with Methodological Aspects 
 
201 
The regulation of the expression of tumour associated transcripts is complex and multi-
factorial and different factors could produce counteracting effects. This study, however, 
demonstrates that by careful analysis of the data it is possible to obtain biologically relevant 
results. 
6. Acknowledgment 
We would like to thank Prof. John Carstensen, Oncological Center, Linköping University 
Hospital for statistical advice. 
7. References 
Bentley, N. J., Eisen, T., and Goding, C. R. (1994). Mol Cell Biol 14, 7996-8006. 
Berking, C., Schlupen, E. M., Schrader, A., Atzpodien, J., and Volkenandt, M. (1999). Arch 
Dermatol Res 291, 479-84. 
Boon, T., and van der Bruggen, P. (1996). J Exp Med 183, 725-9. 
Brasseur, F., Rimoldi, D., Lienard, D., Lethe, B., Carrel, S., Arienti, F., Suter, L., Vanwijck, R., 
Bourlond, A., Humblet, Y., and et al. (1995). Int J Cancer 63, 375-80. 
Brownbridge, G. G., Gold, J., Edward, M., and MacKie, R. M. (2001). Br J Dermatol 144, 279-87. 
Cormier, J. N., Hijazi, Y. M., Abati, A., Fetsch, P., Bettinotti, M., Steinberg, S. M., Rosenberg, 
S. A., and Marincola, F. M. (1998). Int J Cancer 75, 517-24. 
Coulie, P. G., Brichard, V., Van Pel, A., Wolfel, T., Schneider, J., Traversari, C., Mattei, S., De 
Plaen, E., Lurquin, C., Szikora, J. P., Renauld, J. C., and Boon, T. (1994). J Exp Med 
180, 35-42. 
Dalerba, P., Ricci, A., Russo, V., Rigatti, D., Nicotra, M. R., Mottolese, M., Bordignon, C., 
Natali, P. G., and Traversari, C. (1998). Int J Cancer 77, 200-4. 
de Vries, T. J., Fourkour, A., Punt, C. J., van de Locht, L. T., Wobbes, T., van den Bosch, S., de 
Rooij, M. J., Mensink, E. J., Ruiter, D. J., and van Muijen, G. N. (1999). Br J Cancer 80, 
883-91. 
de Vries, T. J., Fourkour, A., Wobbes, T., Verkroost, G., Ruiter, D. J., and van Muijen, G. N. 
(1997). Cancer Res 57, 3223-9. 
Du, J., Miller, A. J., Widlund, H. R., Horstmann, M. A., Ramaswamy, S., and Fisher, D. E. 
(2003). Am J Pathol 163, 333-43. 
Duan, Z., Duan, Y., Lamendola, D. E., Yusuf, R. Z., Naeem, R., Penson, R. T., and Seiden, M. 
V. (2003). Clin Cancer Res 9, 2778-85. 
Fang, D., Kute, T., and Setaluri, V. (2001). Pigment Cell Res 14, 132-9. 
Fang, D., and Setaluri, V. (1999). Biochem Biophys Res Commun 256, 657-63. 
Fetsch, P. A., Steinberg, S. M., Riker, A. I., Marincola, F. M., and Abati, A. (2001). Cancer 93, 
409-14. 
Hanekom, G. S., Stubbings, H. M., Johnson, C. A., and Kidson, S. H. (1999). Melanoma Res 9, 
465-73. 
Hofbauer, G. F., Geertsen, R., Laine, E., Burg, G., and Dummer, R. (2001). Melanoma Res 11, 
213-8. 
Hoon, D. S., Bostick, P., Kuo, C., Okamoto, T., Wang, H. J., Elashoff, R., and Morton, D. L. 
(2000). Cancer Res 60, 2253-7. 
Hoon, D. S., Wang, Y., Dale, P. S., Conrad, A. J., Schmid, P., Garrison, D., Kuo, C., Foshag, L. 
J., Nizze, A. J., and Morton, D. L. (1995). J Clin Oncol 13, 2109-16. 
www.intechopen.com
 
Current Management of Malignant Melanoma 
 
202 
Johansson, M., Takasaki, A., Lenner, L., Årstrand, K., and Kågedal, B. (2002). Melanoma Res 
12, 193-200. 
Johansson, M., Årstrand, K., Håkansson, A., Lindholm, C., and Kågedal, B. (2000). Melanoma 
Res 10, 213-22. 
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, 
T., and Rosenberg, S. A. (1994a). Proc Natl Acad Sci U S A 91, 3515-9. 
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., 
Yannelli, J. R., Adema, G. J., Miki, T., and Rosenberg, S. A. (1994b). Proc Natl Acad 
Sci U S A 91, 6458-62. 
Keilholz, U., Willhauck, M., Scheibenbogen, C., de Vries, T. J., and Burchill, S. (1997). 
Melanoma Res 7 Suppl 2, S133-41. 
Kågedal, B., Farnebäck, M., Håkansson, A., Gustafsson, B., and Håkansson, L. (2007). Clin 
Chem Lab Med 45, 1481-7. 
Lee, P. D., Sladek, R., Greenwood, C. M., and Hudson, T. J. (2002). Genome Res 12, 292-7. 
Mellado, B., Gutierrez, L., Castel, T., Colomer, D., Fontanillas, M., Castro, J., and Estape, J. 
(1999). Clin Cancer Res 5, 1843-8. 
Ohnmacht, G. A., and Marincola, F. M. (2000). J Cell Physiol 182, 332-8. 
Ohnmacht, G. A., Wang, E., Mocellin, S., Abati, A., Filie, A., Fetsch, P., Riker, A. I., Kammula, 
U. S., Rosenberg, S. A., and Marincola, F. M. (2001). J Immunol 167, 1809-20. 
Osella Abate, S., Savoia, P., Cambieri, I., Salomone, B., Quaglino, P., and Bernengo, M. G. 
(2000). Melanoma Res 10, 545-55. 
Pak, B. J., Li, Q., Kerbel, R. S., and Ben-David, Y. (2000). Melanoma Res 10, 499-505. 
Parmiani, G., Castelli, C., Dalerba, P., Mortarini, R., Rivoltini, L., Marincola, F. M., and 
Anichini, A. (2002). J Natl Cancer Inst 94, 805-18. 
Reynolds, S. R., Albrecht, J., Shapiro, R. L., Roses, D. F., Harris, M. N., Conrad, A., 
Zeleniuch-Jacquotte, A., and Bystryn, J. C. (2003). Clin Cancer Res 9, 1497-502. 
Riker, A., Cormier, J., Panelli, M., Kammula, U., Wang, E., Abati, A., Fetsch, P., Lee, K. H., 
Steinberg, S., Rosenberg, S., and Marincola, F. (1999). Surgery 126, 112-20. 
Riker, A. I., Kammula, U. S., Panelli, M. C., Wang, E., Ohnmacht, G. A., Steinberg, S. M., 
Rosenberg, S. A., and Marincola, F. M. (2000). Int J Cancer 86, 818-26. 
Sarantou, T., Chi, D. D., Garrison, D. A., Conrad, A. J., Schmid, P., Morton, D. L., and Hoon, 
D. S. (1997). Cancer Res 57, 1371-6. 
Smith, B., Selby, P., Southgate, J., Pittman, K., Bradley, C., and Blair, G. E. (1991). Lancet 338, 
1227-9. 
Takeuchi, H., Kuo, C., Morton, D. L., Wang, H. J., and Hoon, D. S. (2003). Cancer Res 63, 441-8. 
Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., and 
Speleman, F. (2002). Genome Biol 3, RESEARCH0034. 
Wang, R. F., Appella, E., Kawakami, Y., Kang, X., and Rosenberg, S. A. (1996). J Exp Med 184, 
2207-16. 
Wang, R. F., Robbins, P. F., Kawakami, Y., Kang, X. Q., and Rosenberg, S. A. (1995). J Exp 
Med 181, 799-804. 
Wölfel, T., Van Pel, A., Brichard, V., Schneider, J., Seliger, B., Meyer zum Büschenfelde, K. 
H., and Boon, T. (1994). Eur J Immunol 24, 759-64. 
Yasumoto, K., Yokoyama, K., Shibata, K., Tomita, Y., and Shibahara, S. (1994). Mol Cell Biol 
14, 8058-70. 
Yasumoto, K., Yokoyama, K., Takahashi, K., Tomita, Y., and Shibahara, S. (1997). J Biol Chem 
272, 503-9. 
www.intechopen.com
Current Management of Malignant Melanoma
Edited by Dr. Ming Yu Cao
ISBN 978-953-307-264-7
Hard cover, 274 pages
Publisher InTech
Published online 22, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Management of melanoma is challenging, especially for the late stage of the disease. Development of new
therapies and optimizing current treatments are being pursued in attempt to further improve the survival rate.
The book provides up-to-date knowledge and experience in early diagnosis, prevention and treatment of
melanoma as well as current ongoing clinical studies on melanoma. The book also provides the most recent
perspectives of research on the molecular basis of melanoma, such as melanoma associated genes and a
possible link between stress and melanoma.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Malin Farneba ̈ck, Annika Ha ̊kansson, Leif Ha ̊kansson, Bertil Gustafsson and Bertil Ka ̊gedal (2011). Expression
of Tumour Associated Transcripts in Malignant Melanoma Metastases - with Methodological Aspects, Current
Management of Malignant Melanoma, Dr. Ming Yu Cao (Ed.), ISBN: 978-953-307-264-7, InTech, Available
from: http://www.intechopen.com/books/current-management-of-malignant-melanoma/expression-of-tumour-
associated-transcripts-in-malignant-melanoma-metastases-with-methodological-asp
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
